PolyNovo Limited (ASX:PNV)

Market Cap	645.94M -34.6%
Revenue (ttm)	139.49M +20.7%
Net Income	9.88M +67.3%
EPS	0.01 +67.6%
Shares Out	690.84M
PE Ratio	66.45
Forward PE	43.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,917,649
Average Volume	2,828,032
Open	0.9700
Previous Close	0.9400
Day's Range	0.9050 - 0.9700
52-Week Range	0.8650 - 1.7150
Beta	1.43
RSI	44.53
Earnings Date	Feb 20, 2026

About PolyNovo

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to tre...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 301
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PNV

Financial Performance

In fiscal year 2025, PolyNovo's revenue was 128.70 million, an increase of 24.67% compared to the previous year's 103.23 million. Earnings were 13.21 million, an increase of 151.17%.